Chemomab Therapeutics Ltd (STU:2QV0)
€ 1.68 0.1 (6.33%) Market Cap: 29.80 Mil Enterprise Value: 11.80 Mil PE Ratio: 0 PB Ratio: 1.92 GF Score: 33/100

Chemomab Therapeutics Ltd at JMP Securities Life Sciences Conference Transcript

Jun 16, 2022 / 03:00PM GMT
Release Date Price: €3.1 (+2.65%)
Jon Wolleben
JMP Securities LLC - Senior Analyst

My name is Jon Wolleben, Senior Analyst here at JMP. And we're pleased to have the team from Chemomab -- and CEO, Dale Pfost, who will be giving us an overview of the company. This is a first-in-class novel mechanism that's going after two really hard to treat diseases with high unmet need. So -- interested to dig in a little bit this morning and we'll save time for questions at the end. So thank you, Dale.

Dale Pfost
Chemomab Therapeutics Ltd. - CEO & Chairman

Thank you. Please refer to our forward-looking statements and risk factors, including those on file with the SEC. Chemomab is a clinical-stage biotech company. Our focus is developing innovative therapies for rare, inflammatory and fibrotic disease with high unmet need. We believe we have a unique story with substantial clinical and commercial potential.

CM-101 is a pipeline in a product, and is a first-in-class monoclonal antibody that neutralizes CCL24, a novel target at the confluence of fibrosis and inflammation. Our clinical program is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot